Information for the patient
Ô This card contains important safety information that you
should know before you are given CAPRELSA and during
treatment with CAPRELSA
Ô Show this card to any doctor involved in your treatment. If you get
The Medicines Authority Post-licensing Directorate, Sir Temi Żammit
Buildings, Malta Life Sciences Park, San Gwann SGN 3000
MALTA Website: www.medicinesauthority.gov.mt/adrportal email
By reporting side effects you can help provide more information

CAPRELSA can cause a change in the electrical activity of your heart called QTc prolongation, which can cause irregular heartbeats and lifethreatening changes in heart rhythm.

A syndrome of the brain called posterior reversible encephalopathy syndrome (PRES; also known as reversible posterior leukoencephalopathy syndrome [RPLS]) can occur while taking CAPRELSA.

During CAPRELSA treatment, telephone your doctor or tell your carer immediately if you:

- Ô Feel faint, dizzy or feel your heart beating irregularly, as these may be symptoms related to QTc prolongation
- Ô Experience headaches, seizures, convulsions, confusion, problems seeing or problems thinking, as these may be symptoms of PRES

Do not stop taking CAPRELSA, or change your dose, unless told to by your doctor.

If you take too many CAPRELSA tablets, telephone your doctor immediately.

Approval ID: GZEMEA.CAPR.16.09.0455 DOP: September 2016

new safety information. You can help by reporting any side effects you may get. See www.website.com for how to report side effects

This medicine is subject to additional monitoring. This will allow quick identication of

Patient Alert Card: CAPRELSA® ▼ (vandetanib)

See the CAPRELSA Package Leaflet for more information

Please make sure that you have a list of all your other medicines with you at any visit to your doctor

[–] :əman zitnəita[–]

Doctoris name: -----

SANOFI GENZYME 🎝

Doctoris telephone number:

Start date of CAPRELSA treatment: